If this email does not display properly, click here
Newsletter #2
Winter 2021

Letter from the Editors

Welcome to the second issue of Nutritional Therapy for IBD’s quarterly newsletter.

We are excited about the growing interest in nutritional therapy and the increasing number of clinicians and patients utilizing the Nutritional Therapy for IBD website as a primary resource to learn about the role of nutrition in the management of IBD. To better serve the needs of patients, we are working diligently now on an exciting new expanded experience of patient information and resources described as the Patient Pathway, with more information to share in the coming months.

Publications and Research Updates

As we strive to keep the website as current as possible, we have added several new and interesting publications since last quarter, including the following:
Impact of Diet on Inflammatory Bowel Disease Symptoms: An Adolescent Viewpoint 
Authors: Zangara MT et al
Crohn's & Colitis 360, Volume 2, Issue 4, October 2020, otaa084

A survey of 132 adolescent patients at Cleveland Clinic reveals that this population perceives a relationship between diet and disease symptoms and is interested in dietary modifications as a management option.
Diet in Treatment of Inflammatory Bowel Diseases
Authors: Sasson AN et al
Citation: Clin Gastroenterol Hepatol. 2021 Mar;19(3):425-435.e3. doi: 10.1016/j.cgh.2019.11.054. Epub 2019 Dec 5.

This review reports findings from studies of the effects of dietary patterns, single micronutrients, and food additives in inducing and maintaining remission in patients with IBD. The authors further discuss future directions for research and propose a framework for studies of dietary interventions in the treatment of IBD.
Randomised Clinical Trial: Exclusive Enteral Nutrition Versus Standard of Care for Acute Severe Ulcerative Colitis
Authors: Sahu P et al
Aliment Pharmacol Ther. 2021 Jan 13. doi: 10.1111/apt.16249

Patients who completed a 7 day course of EEN combined with SOC had a shorter hospital stay [median (range) 10 (8-17) vs 13 (8-24) days; P = 0.04], higher day 7 albumin level (34 ± 4 vs 29 ± 3 g/L, P < 0.01), greater reduction in serum C-reactive protein and faecal calprotectin levels (both P = 0.04) and a lower composite outcome of colectomy/hospitalisation at 6 months (16% vs 39%; P = 0.045) compared to SOC.

Website Updates

Mental health is an increasing public health concern, particularly during the era of COVID-19. The rates of depression and anxiety are rising at alarming rates in the adolescent general population. These disorders have also been long-standing, yet increasing, comorbidities in the IBD population. A new research page has been added to the website dedicated to the gut-brain axis and the potential for dietary therapy to impact mental health via its relationship with the gut microbiota. Many new and interesting publications related to the gut-brain axis and potential mechanisms related to IBD, including altered immunity and stress response, are highlighted.

News and Events

Nutritional Therapy for IBD had its third annual exhibit at the Crohn’s and Colitis Congress where Gauree Konijeti, MD, Lori Beeken, RD, and Barbara Olendzki, RD, joined us for discussion in the Meet the Professors and Practitioners program.
Highlights of nutritional presentations from Congress include the following:

Now Enrolling - Clinical Trials

The MELODY Trial: Modulating Early Life Microbiome Through Dietary Intervention in Crohn's Disease (IBD-AID)

The MELODY Trial, conducted by the University of Massachusetts Medical School and the Icahn School of Medicine at Mount Sinai, will test whether a non­invasive diet intervention (IBD-AID) implemented during the third trimester of pregnancy can beneficially shift the microbiome in patients with CD and UC and in their babies. This trial has recently expanded enrollment to include patients with ulcerative colitis.

Click Here for enrollment information.
Click Here to download brochure.

SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis

In this study conducted by Massachusetts General Hospital, investigators hope to find out if dietary therapy by either the Specific Carbohydrate Diet (SCD) or the Mediterranean Diet (MD) will help improve ulcerative colitis symptoms for patients with mild to moderately active disease. In addition, the investigators will compare disease activity and changes in the intestinal bacterial composition in the colon that occur with the MD or the SCD in active ulcerative colitis.

Click Here to download a PDF with enrollment information.


We thank all of the Medical Advisors on our Medical Advisory Board for their contributions to content, nutritional research, and participation at exhibits providing lectures and/or sharing their medical expertise to field questions regarding nutrition and IBD. We welcome our newest member, Ashwin N. Ananthakrishnan, MD, MPH, Director of Massachusetts General Hospital Crohn’s and Colitis Center and Associate Professor of Medicine at Harvard Medical School.

Thank you for reading the updates from Nutritional Therapy for IBD. We appreciate your interest in advocacy for nutritional therapy in the management of IBD!

NTforIBD Publishing Team

Website Website
Twitter Twitter
Facebook Facebook
YouTube Channel YouTube Channel
Copyright © 2021 Nutritional Therapy for IBD, All rights reserved.